• BioNxt launched a non-brokered private placement under the listed issuer financing exemption, targeting up to USD 2 million in gross proceeds.
• Offering priced at USD 0.33 per unit, with up to 6,060,606 units to be issued; no minimum financing condition.
• Each unit includes one common share, one warrant exercisable at USD 0.5 for 24 months from closing.
• Proceeds earmarked for European R&D, operations, working capital, general corporate purposes; closing expected before July 27, 2026.
• Finder’s fees up to 6% of gross proceeds, with up to 6% finder’s warrants at USD 0.5 for 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606121715ACCESSWRNAPR_____1176737) on June 12, 2026, and is solely responsible for the information contained therein.